Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ELDORADO phase III trial of doravirine versus dolutegravir-based first-line antiretroviral therapy in treatment-naive adults with HIV-1
2023-508626-10-00Phase 3Authorised
- Sponsor
- Inserm
- Start
- Jan 2025
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 3, randomised, open-label trial of doravirine, dolutegravir, lamivudine, tenofovir disoproxil fumarate and emtricitabine in Human immunodeficiency virus infection type 1 (2 arms), sponsored by Inserm. Primary endpoint: Virologic success at Week 48. Planned start Jan 2025; status: authorised.
02
Drugs
doravirinedolutegravirlamivudinetenofovir disoproxil fumarateemtricitabine
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on 2023-508626-10-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508626-10-00.